The bitter pill of the loss of the European Medicines Agency (EMA) from London may be sweetened by the news of both inward and domestic investments announced during 2017, and the possibility of closer scrutiny of formulation and production of post-Brexit UK therapies by the EU may be balanced by the LifeSciences sector deal in the Government’s Industrial Strategy. Sarah Houlton reports.
A 250-page review of 2017 in the manufacturing, engineering and technology sectors, written by experts